English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Treatment with bioresorbable magnesium scaffolds (Magmaris, Biotronik AG, Bülach, Switzerland) is recommended only for stable angina pectoris [1]. Confirmation of promising results using Magmaris in acute coronary syndrome (ACS) can be found in recently published registries [2]. A 57-year-old woman with typical risk factors (hypertension, hyperlipidemia) was admitted to the CathLab because of non-ST-segment elevation ACS. Coronary angiography showed a severe lesion at the proximal part of the left anterior descending artery (Figure 1A). The lesion characteristics (focal, concentric, smooth contour without calcification and thrombus) were encouraging for bioresorbable magnesium scaffolding. The lesion was predilated with a 3.5 mm at 16 atm non-compliant balloon, followed by implantation of a 3.5 × 20.0 mm bioresorbable magnesium scaffold at 16 atm; post-dilation was performed with a 3.5 mm at 16 atm non-compliant balloon. Optimal results (device expansion, struts apposition, no edge dissection) were confirmed on the final angiography (Figure 1B) and optical coherence tomography (OCT) assessment (Figure 1D). Three days later, the patient was discharged on aspirin and ticagrelor.

Multimodality imaging results of neointimal healing after magnesium scaffold implantation in an acute coronary syndrome setting